[{"id":"5216fc75-03db-4204-a70d-358dda4f246f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06023758","created_at":"2023-09-05T18:12:35.831Z","updated_at":"2024-07-02T16:35:04.409Z","phase":"Phase 2","brief_title":"Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC","source_id_and_acronym":"NCT06023758","lead_sponsor":"Peking University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • erfonrilimab (KN046) • anbenitamab (KN026)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-10"},{"id":"62515fcb-d753-4019-96db-b94b15aec588","acronym":"","url":"https://clinicaltrials.gov/study/NCT04040699","created_at":"2021-01-17T17:35:46.592Z","updated_at":"2024-07-02T16:35:10.718Z","phase":"Phase 1","brief_title":"KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor","source_id_and_acronym":"NCT04040699","lead_sponsor":"Peking University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erfonrilimab (KN046) • anbenitamab (KN026)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 09/26/2019","start_date":" 09/26/2019","primary_txt":" Primary completion: 09/22/2022","primary_completion_date":" 09/22/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2024-04-09"},{"id":"ed80d679-9916-475a-bee2-a4fd8d3172b6","acronym":"KN026-202","url":"https://clinicaltrials.gov/study/NCT03925974","created_at":"2021-01-18T19:18:44.398Z","updated_at":"2024-07-02T16:35:15.243Z","phase":"Phase 2","brief_title":"KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT03925974 - KN026-202","lead_sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anbenitamab (KN026)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 06/17/2019","start_date":" 06/17/2019","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 05/31/2022","study_completion_date":" 05/31/2022","last_update_posted":"2024-03-12"},{"id":"813611ea-c751-492d-8b93-00e4274c3dfe","acronym":"","url":"https://clinicaltrials.gov/study/NCT05427383","created_at":"2022-06-22T22:54:12.791Z","updated_at":"2024-07-02T16:35:25.799Z","phase":"Phase 2/3","brief_title":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","source_id_and_acronym":"NCT05427383","lead_sponsor":"Shanghai JMT-Bio Inc.","biomarkers":" HER-2 • CEACAM5 • CA 19-9","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2 • CEACAM5 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • irinotecan • anbenitamab (KN026)"],"overall_status":"Recruiting","enrollment":" Enrollment 286","initiation":"Initiation: 04/07/2022","start_date":" 04/07/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2023-12-19"},{"id":"bfd133ba-4207-42a9-a0dd-8e750a9eae6b","acronym":"HERCKER-01","url":"https://clinicaltrials.gov/study/NCT05985707","created_at":"2023-08-14T16:10:12.961Z","updated_at":"2024-07-02T16:35:39.614Z","phase":"Phase 2","brief_title":"KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma","source_id_and_acronym":"NCT05985707 - HERCKER-01","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" HER-2 • KRAS • BRAF","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • RAS wild-type • RAS wild-type + BRAF wild-type","tags":["HER-2 • KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • RAS wild-type • RAS wild-type + BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • erfonrilimab (KN046) • anbenitamab (KN026)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/15/2023","start_date":" 08/15/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-08-21"},{"id":"6eabeaef-b53c-4a96-934c-7b0bdb886f28","acronym":"","url":"https://clinicaltrials.gov/study/NCT05838066","created_at":"2023-05-01T14:04:11.602Z","updated_at":"2025-02-25T12:29:31.332Z","phase":"Phase 3","brief_title":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.","source_id_and_acronym":"NCT05838066","lead_sponsor":"Shanghai JMT-Bio Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • anbenitamab (KN026)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 880","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-05-01"},{"id":"639cd6a6-ce7e-438e-b3d5-5ca875301775","acronym":"","url":"https://clinicaltrials.gov/study/NCT04881929","created_at":"2021-05-11T11:53:06.199Z","updated_at":"2024-07-02T16:36:08.429Z","phase":"Phase 2","brief_title":"Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer","source_id_and_acronym":"NCT04881929","lead_sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • anbenitamab (KN026)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 11/15/2022","primary_completion_date":" 11/15/2022","study_txt":" Completion: 02/15/2023","study_completion_date":" 02/15/2023","last_update_posted":"2022-06-22"}]